Skip to main content
. 2020 Aug 25;26(2):371–380. doi: 10.1007/s10741-020-10016-2

Fig. 2.

Fig. 2

Seesaw role of ACE2 in using (left) or misusing (right) RAS inhibitors in COVID-19 patients, which in both cases is accompanied by adverse consequences especially on the pulmonary and cardiovascular systems, respectively. ACE2, angiotensin-converting enzyme II; RAS, renin-angiotensin system; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2